Integra Therapeutics

Integra Therapeutics develops next-generation gene editing tools by combining CRISPR systems with the gene transfer efficiency of viral integrases and transposases. This approach enables the introduction of DNA into the genome with sequence-specific DNA binding proteins for developing gene therapies, potentially improving the precision and efficiency of therapeutic gene insertion compared to existing technologies. Founded in 2021 and headquartered in Barcelona, Spain, Integra Therapeutics has raised approximately $19.2M in Seed funding from investors including Takeda, Invivo Ventures, Advent France Biotechnology, Columbus Venture Partners, European Innovation Council, and European Investment Bank. The company employs 23 people and addresses limitations of current gene editing approaches by developing tools that can achieve safe, targeted integration of therapeutic genes into specific genomic locations, which is critical for treating genetic diseases requiring permanent correction of disease-causing mutations.